Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.

Novo Nordisk A/S

Eli Lilly and Company

Pfizer Inc.

Viking Therapeutics, Inc.

Kailera Therapeutics, Inc.

Amgen Inc.

MBX Biosciences, Inc. Common Stock

AstraZeneca PLC

Structure Therapeutics Inc.

Gilead Sciences, Inc.

Healthcare

Cash & Others

Technology

Roundhill Investments - GLP-1 & Weight Loss ETF

OZEM Holdings & Sector Breakdown